Altoida
Altoida is defining a new category in neurological care with its first-of-its-kind, multi-modal platform engineered to bring clinical-grade cognitive and functional diagnostics to the front lines of healthcare. Combining augmented reality (AR), sensor fusion, and explainable AI, Altoida's Digital NeuroMarker Platform delivers a 10-minute, self-administered assessment designed for both in-clinic and remote use, capturing hundreds of digital biomarkers across motor, speech, AR, and cognitive domains. The platform is intended to detect signs of Mild Cognitive Impairment (MCI) and Alzheimer's disease earlier and more objectively than traditional clinical methods. Backed by over 20 years of scientific research and shaped by nearly 20,000 participants and tens of thousands of assessments, Altoida's platform is being used in research by global pharmaceutical leaders to support clinical trial enrichment, optimized screening, treatment monitoring, and disease progression research. With platform extensibility for conditions like Parkinson's, traumatic brain injury, and depression, Altoida aims to build the diagnostic infrastructure for precision brain health at a global scale. The platform is currently intended for investigational use only and has not received FDA clearance.
Altoida
Altoida is defining a new category in neurological care with its first-of-its-kind, multi-modal platform engineered to bring clinical-grade cognitive and functional diagnostics to the front lines of healthcare. Combining augmented reality (AR), sensor fusion, and explainable AI, Altoida's Digital NeuroMarker Platform delivers a 10-minute, self-administered assessment designed for both in-clinic and remote use, capturing hundreds of digital biomarkers across motor, speech, AR, and cognitive domains. The platform is intended to detect signs of Mild Cognitive Impairment (MCI) and Alzheimer's disease earlier and more objectively than traditional clinical methods. Backed by over 20 years of scientific research and shaped by nearly 20,000 participants and tens of thousands of assessments, Altoida's platform is being used in research by global pharmaceutical leaders to support clinical trial enrichment, optimized screening, treatment monitoring, and disease progression research. With platform extensibility for conditions like Parkinson's, traumatic brain injury, and depression, Altoida aims to build the diagnostic infrastructure for precision brain health at a global scale. The platform is currently intended for investigational use only and has not received FDA clearance.
TL;DR
Product: Digital NeuroMarker Platform — 10-minute multimodal (AR, sensor, speech, motor) self-administered cognitive/functional assessment
Use case: Detect early signs of MCI and Alzheimer’s; support research, clinical trial enrichment, screening, and monitoring
Regulatory status: Intended for investigational use only; not FDA cleared
Evidence base: Built on 20+ years of research and tens of thousands of assessments
28